MX2022008139A - Compuestos de glp-1 de acción prolongada. - Google Patents
Compuestos de glp-1 de acción prolongada.Info
- Publication number
- MX2022008139A MX2022008139A MX2022008139A MX2022008139A MX2022008139A MX 2022008139 A MX2022008139 A MX 2022008139A MX 2022008139 A MX2022008139 A MX 2022008139A MX 2022008139 A MX2022008139 A MX 2022008139A MX 2022008139 A MX2022008139 A MX 2022008139A
- Authority
- MX
- Mexico
- Prior art keywords
- comparable
- glp
- compound
- long
- better
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 abstract 1
- 108010019598 Liraglutide Proteins 0.000 abstract 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002701 liraglutide Drugs 0.000 abstract 1
- 229950011186 semaglutide Drugs 0.000 abstract 1
- 108010060325 semaglutide Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
- Pens And Brushes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un nuevo derivado GLP-1, en comparación con derivados GLP-1 como la liraglutida y la semaglutida que están en el mercado, tiene un efecto, potencia o eficacia comparable o mejor, una duración de acción in vivo o vida media in vivo más larga o comparable, una afinidad de unión al receptor GLP-1 mejor o comparable y una estabilidad DPP-IV mejor o comparable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911397405 | 2019-12-30 | ||
CN202011053306 | 2020-09-29 | ||
PCT/CN2020/141057 WO2021136303A1 (zh) | 2019-12-30 | 2020-12-29 | 长效glp-1化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008139A true MX2022008139A (es) | 2022-10-03 |
Family
ID=76687327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008139A MX2022008139A (es) | 2019-12-30 | 2020-12-29 | Compuestos de glp-1 de acción prolongada. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4086277A4 (es) |
JP (1) | JP2023510218A (es) |
KR (1) | KR20220119731A (es) |
CN (1) | CN114901680A (es) |
AU (1) | AU2020418207A1 (es) |
BR (1) | BR112022013042A2 (es) |
CA (1) | CA3166496A1 (es) |
MX (1) | MX2022008139A (es) |
WO (1) | WO2021136303A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022210988B9 (en) | 2021-01-20 | 2024-02-22 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
AU2022386489A1 (en) * | 2021-11-12 | 2024-05-23 | Fujian Shengdi Pharmaceutical Co., Ltd. | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
DK336188D0 (da) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | Propeptider |
AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
CN1056618C (zh) | 1993-09-17 | 2000-09-20 | 诺沃挪第克公司 | 酰化的胰岛素和含有这种胰岛素的药物组合物 |
AU1272295A (en) | 1993-12-17 | 1995-07-03 | Novo Nordisk A/S | Proinsulin-like compounds |
US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
KR0150565B1 (ko) | 1995-02-15 | 1998-08-17 | 김정재 | 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법 |
IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
DE69737479D1 (de) | 1996-08-30 | 2007-04-26 | Novo Nordisk As | Glp-1 derivate |
EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
ES2526924T3 (es) * | 2007-08-15 | 2015-01-16 | Novo Nordisk A/S | Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol |
CN101784562B (zh) * | 2007-08-15 | 2016-07-13 | 诺沃-诺迪斯克有限公司 | 具有酰基和亚烷基二醇部分的胰岛素类似物 |
JP2010538049A (ja) * | 2007-09-05 | 2010-12-09 | ノボ・ノルデイスク・エー/エス | 切断型glp−1誘導体及びその治療的使用 |
WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
PT2254906T (pt) * | 2008-03-18 | 2017-01-03 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
EP3922260A3 (en) * | 2016-05-24 | 2022-06-15 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
WO2019200594A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
JP2023510219A (ja) * | 2019-12-30 | 2023-03-13 | ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド | インスリン誘導体 |
-
2020
- 2020-12-29 BR BR112022013042A patent/BR112022013042A2/pt unknown
- 2020-12-29 CA CA3166496A patent/CA3166496A1/en active Pending
- 2020-12-29 AU AU2020418207A patent/AU2020418207A1/en active Pending
- 2020-12-29 KR KR1020227026310A patent/KR20220119731A/ko unknown
- 2020-12-29 CN CN202080091240.0A patent/CN114901680A/zh active Pending
- 2020-12-29 JP JP2022540870A patent/JP2023510218A/ja active Pending
- 2020-12-29 WO PCT/CN2020/141057 patent/WO2021136303A1/zh unknown
- 2020-12-29 MX MX2022008139A patent/MX2022008139A/es unknown
- 2020-12-29 EP EP20909624.7A patent/EP4086277A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4086277A1 (en) | 2022-11-09 |
AU2020418207A1 (en) | 2022-08-25 |
CA3166496A1 (en) | 2021-07-08 |
BR112022013042A2 (pt) | 2022-10-18 |
JP2023510218A (ja) | 2023-03-13 |
CN114901680A (zh) | 2022-08-12 |
EP4086277A4 (en) | 2024-02-14 |
WO2021136303A1 (zh) | 2021-07-08 |
KR20220119731A (ko) | 2022-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ739250A (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
PH12018502742A1 (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
SA518391903B1 (ar) | معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي | |
MY193616A (en) | Gip and glp-1 co-agonist compounds | |
ZA202102353B (en) | Conjugation linkers containing 2,3-diaminosuccinyl group | |
MX2022008139A (es) | Compuestos de glp-1 de acción prolongada. | |
EP3946460A4 (en) | IMPROVED CONJUGATION LINKERS | |
EA201391764A1 (ru) | Агонисты рецептора glp-1/глюкагона длительного действия | |
MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. | |
MX370666B (es) | Novedosos moduladores del receptor de péptido tipo glucagón 1 (glp-1). | |
MX2018001511A (es) | Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos. | |
EA201790254A1 (ru) | Новые модуляторы рецептора glp-1 | |
MY186251A (en) | Long-acting insulin and use thereof | |
MX2020004453A (es) | Conjugados de accion prolongada de derivados de glp-2. | |
MX2022001719A (es) | Formulaciones de conjugados de benzazepina y usos de las mismas. | |
PH12017501205A1 (en) | Glucagon derivatives | |
EP3660019C0 (en) | 7H-PYRAZOLO[3,4-D]TRIAZINE-2-OXIDES AS EXPLOSIVES | |
GEP20247585B (en) | Furoindazole derivatives | |
IL291315A (en) | A stable and concentrated radiopharmaceutical preparation | |
MX2022006737A (es) | Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. | |
MX2019009235A (es) | Compuestos antifibroticos. | |
MX2020003616A (es) | Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene. | |
MX2022006097A (es) | Compuesto que comprende un acido nucleico y un motivo de extension de la vida media. | |
TN2021000076A1 (en) | Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof | |
NZ739892A (en) | Methods and formulations for reducing bovine emissions |